BoNT/A1 Secondary Failure for the Treatment of Neurogenic Detrusor Overactivity: An Ex Vivo Functional Study

Management of neurogenic detrusor overactivity (NDO) remains a clinical priority to improve patients’ quality of life and prevent dramatic urological complications. Intradetrusor injection of onabotulinumtoxinA (BoNT/A1, botulinum neurotoxin A1) is approved as second therapeutic line in these patien...

Full description

Bibliographic Details

Published in:	Toxins
Main Authors:	Jacquie Maignel, Vincent Martin, Rana Assaly, Mathieu L. Vogt, Kevin Retailleau, Fraser Hornby, Alexandra Laugerotte, Stéphane Lezmi, Pierre Denys, Johannes Krupp, Charles Joussain
Format:	Article
Language:	English
Published:	MDPI AG 2022-01-01
Subjects:	neurogenic bladder treatment failure botulinum A toxin NDO mechanism of action
Online Access:	https://www.mdpi.com/2072-6651/14/2/77